NCT00636961

An Exploratory Study, to Assess the Effect of Repeat-dose Inhaled Indacaterol Maleate (300 μg) on Dynamic and Static Lung Hyperinflation, Subjective Breathlessness and Health Status in Patients With Chronic Obstructive Pulmonary Disease(COPD)

An Exploratory, Double Blind, Randomized, Placebo-controlled, 2-way Cross-over Study to Assess the Effect of Repeat-dose Inhaled Indacaterol Maleate (300 μg) on Dynamic and Static Lung Hyperinflation, Subjective Breathlessness and Health Status in Patients With COPD

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 27 (actual)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 40 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study evaluated the effect of QAB149 on dynamic and static hyperinflation, breathlessness, and health status in COPD patients

Conditions

• Chronic Obstructive Pulmonary Disease

Interventions

Type	Name	Description
DRUG	Indacaterol 300μg	300μg indacaterol maleate inhalation powder in hard gelatin capsules administered via Concept1 inhalation device
DRUG	Placebo	Matching placebo devices and hard gelatin capsules

Timeline

• Start date: 2008-02-01
• Primary completion: 2008-08-01
• Completion: 2008-08-01
• First posted: 2008-03-17
• Last updated: 2011-08-30
• Results posted: 2011-08-30

Locations

3 sites across 1 country: Germany